Xu Y - Search Results

1

A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice.

Xu Y, Zhang X, Wang Y, Pan M, Wang M, Zhang J. Xu Y, et al. Cancer Immunol Immunother. 2019 Sep;68(9):1429-1441. doi: 10.1007/s00262-019-02379-9. Epub 2019 Aug 19. Cancer Immunol Immunother. 2019. PMID: 31428800 Free PMC article.

2

Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.

Ma Z, He H, Sun F, Xu Y, Huang X, Ma Y, Zhao H, Wang Y, Wang M, Zhang J. Ma Z, et al. Among authors: xu y. J Cancer Res Clin Oncol. 2017 Oct;143(10):1929-1940. doi: 10.1007/s00432-017-2436-0. Epub 2017 May 23. J Cancer Res Clin Oncol. 2017. PMID: 28536738

3

[Transglutaminase-based antibody-drug conjugation: antibody site-specific mutation and identification].

Ma ZX, Xu Y, Zhao H, Sun FM, Zhang XR, Wang M, Zhang J. Ma ZX, et al. Among authors: xu y. Yao Xue Xue Bao. 2017 Mar;52(3):403-8. Yao Xue Xue Bao. 2017. PMID: 29979846 Chinese.

4

Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma.

Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X, Lv T, Zhang Y, Wang M, Huang Z, Zhang J. Sun F, et al. Among authors: xu y. Cancer Res. 2019 Jul 1;79(13):3395-3405. doi: 10.1158/0008-5472.CAN-18-2839. Epub 2019 Mar 27. Cancer Res. 2019. PMID: 30918001

5

Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.

Xu Y, Xiao Y, Luo C, Liu Q, Wei A, Yang Y, Zhao L, Wang Y. Xu Y, et al. Int Immunopharmacol. 2020 Jul;84:106584. doi: 10.1016/j.intimp.2020.106584. Epub 2020 May 15. Int Immunopharmacol. 2020. PMID: 32422527

6

The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.

Xu Y, Hezam K, Ali MG, Wang Y, Zhang J. Xu Y, et al. Immunopharmacol Immunotoxicol. 2021 Jun;43(3):386-394. doi: 10.1080/08923973.2021.1924195. Epub 2021 May 20. Immunopharmacol Immunotoxicol. 2021. PMID: 34014122

7

A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.

Liu Q, Song Q, Luo C, Wei J, Xu Y, Zhao L, Wang Y. Liu Q, et al. Among authors: xu y. Mol Immunol. 2023 Oct;162:125-132. doi: 10.1016/j.molimm.2023.08.007. Epub 2023 Sep 6. Mol Immunol. 2023. PMID: 37677989

8

Discovery of Novel and Selective G-Protein Coupled Receptor 120 (GPR120) Agonists for the Treatment of Type 2 Diabetes Mellitus.

Wang X, Li X, Wei S, Wang M, Xu Y, Hu W, Gao Z, Liu R, Wang S, Ji G. Wang X, et al. Among authors: xu y. Molecules. 2022 Dec 17;27(24):9018. doi: 10.3390/molecules27249018. Molecules. 2022. PMID: 36558150 Free PMC article.

9

Comparison of the efficacy between Super-Path and Watson-Jones approaches in the management of early femoral head necrosis.

Xu Y, Zeng P. Xu Y, et al. Medicine (Baltimore). 2025 Jan 24;104(4):e41391. doi: 10.1097/MD.0000000000041391. Medicine (Baltimore). 2025. PMID: 39854751

10

Steering the Absorption Configuration of Intermediates over Pd-Based Electrocatalysts toward Efficient and Stable CO₂ Reduction.

Wei S, Xu Y, Song T, Dai H, Li F, Gao X, Zhai Y, Gong S, Li R, Zhang X, Chan K. Wei S, et al. Among authors: xu y. J Am Chem Soc. 2025 Jan 24. doi: 10.1021/jacs.4c14253. Online ahead of print. J Am Chem Soc. 2025. PMID: 39854612

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,853 results

Search Page

Filters